IPI-145 by Infinity is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, used in the treatment of hematologic cancers and inflammatory conditions.
IPI-145 is currently undergoing two Phase 1 clinical trials by Infinity.
The first double-blind, randomized, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of IPI-145 in healthy adult subjects.
The second trial is an open-label, dose-escalation study intended to assess the safety, pharmacokinetics and clinical activity of IPI-145 in patients with advanced hematologic malignancies.